









Markets
/
Stocks
/
nasdaq-abcl
/

Abcellera Biologics Inc

ABCL

3.160USD

+0.380+13.67%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

944.88MMarket Cap

LossP/E TTM



Abcellera Biologics Inc

3.160

+0.380+13.67%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Abcellera Biologics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Abcellera Biologics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 108 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.83.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Abcellera Biologics Inc's Score

Industry at a Glance

Industry Ranking

108 / 392

Overall Ranking

238 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Abcellera Biologics Inc Highlights

StrengthsRisks

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Growing

The company is in a growing phase, with the latest annual income totaling USD 28.83M.

Fairly Valued

The company’s latest PE is -5.48, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 112.27M shares, decreasing 0.09% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 42.69K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.75.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.833

Target Price

+253.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Abcellera Biologics Inc is 6.11, ranking 287 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 8.96M, representing a year-over-year increase of 37.62%, while its net profit experienced a year-over-year increase of 11.76%.

Score

Industry at a Glance

Previous score

6.11

Change



Financials

5.46

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.87

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.47

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.14

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Abcellera Biologics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Abcellera Biologics Inc is 7.59, ranking 99 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.48, which is -466.69% below the recent high of 20.10 and -681.83% above the recent low of -42.86.

Score

Industry at a Glance

Previous score

7.59

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 108/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Abcellera Biologics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 16.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.833

Target Price

+200.71%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Abcellera Biologics Inc

ABCL

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Abcellera Biologics Inc is 6.83, ranking 159 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.42 and the support level at 2.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.50

Change

0.33

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.274

Sell

RSI(14)

37.455

Neutral

STOCH(KDJ)(9,3,3)

15.822

Buy

ATR(14)

0.315

High Vlolatility

CCI(14)

-124.154

Sell

Williams %R

80.285

Oversold

TRIX(12,20)

-0.409

Sell

StochRSI(14)

92.389

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.246

Sell

MA10

3.574

Sell

MA20

3.940

Sell

MA50

3.746

Sell

MA100

4.358

Sell

MA200

3.931

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Abcellera Biologics Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 50.73%, representing a quarter-over-quarter decrease of 1.98%. The largest institutional shareholder is James Simons, holding a total of 3.36M shares, representing 1.12% of shares outstanding, with 15.79% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Thermopylae Holdings Ltd

55.92M

-0.40%

Baker Bros. Advisors LP

27.53M

Capital World Investors

13.36M

Two Sigma Investments, LP

9.99M

+22.09%

Lecault (Veronique)

9.61M

ArrowMark Colorado Holdings, LLC

4.11M

Renaissance Technologies LLC

Star Investors

3.36M

+1.61%

Tang Capital Management, LLC

2.60M

Morgan Stanley & Co. LLC

2.56M

+234.13%

Millennium Management LLC

2.43M

-28.49%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Abcellera Biologics Inc is 4.09, ranking 110 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.88. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.